Results 11 to 20 of about 5,550 (196)

Clinical Associations of Anti‐RNPC3 Autoantibodies in Mixed Connective Tissue Disease [PDF]

open access: yesACR Open Rheumatol
Objective The RNA‐binding region‐containing protein 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous reports, patients with systemic sclerosis (SSc) with anti‐RNPC3 autoantibodies had an increased risk of interstitial lung disease (ILD), severe gastrointestinal (GI) disease, and cancer.
Jalaledin D   +14 more
europepmc   +2 more sources

A Cross-Sectional Study Shows Emergence of the Delta, 19B, 20A, 20B, 19A, and Omicron Variants of SARS-CoV-2 in Burkina Faso: A Conundrum Within a Conundrum. [PDF]

open access: yesHealth Sci Rep
ABSTRACT Context and Objective SARS‐CoV‐2 is an RNA virus that emerged in Wuhan, China. Adaptive mutations in its genome can influence the virus's pathogenicity, enhance its ability to evade the host immune system, and complicate vaccine development. This study aimed to identify the circulating SARS‐CoV‐2 variants in Burkina Faso and trace their origin.
Lallogo TD   +20 more
europepmc   +2 more sources

Exploring Cultural Influences in the Associations Between Emotion Regulation and Mental Health: A Systematic Review Comparing East Asian and Western Cultural Contexts. [PDF]

open access: yesClin Psychol Psychother
ABSTRACT Culture shapes how individuals perceive, experience and regulate emotions. Emotion regulation literature, which informs current understandings of emotional disorders, is largely guided by Western frameworks. This review aimed to systematically examine cultural influences on emotion regulation use, and associated mental health outcomes, among ...
Qiu LS   +5 more
europepmc   +2 more sources

Prognostic predictions in psychosis: exploring the complementary role of machine learning models [PDF]

open access: yesBMJ Mental Health
Background Predicting outcomes in schizophrenia spectrum disorders is challenging due to the variability of individual trajectories. While machine learning (ML) shows promise in outcome prediction, it has not yet been integrated into clinical practice ...
Metten Somers   +31 more
doaj   +2 more sources

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program [PDF]

open access: yesSchizophrenia
Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level.
Johanna T. W. Wigman   +80 more
doaj   +2 more sources

Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative [PDF]

open access: yesSchizophrenia
Speech-based detection of early psychosis is progressing at a rapid pace. Within this evolving field, the Accelerating Medicines Partnership® in Schizophrenia (AMP® SCZ) is uniquely positioned to deepen our understanding of how language and related ...
Zarina R. Bilgrami   +77 more
doaj   +2 more sources

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program [PDF]

open access: yesSchizophrenia
Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team ...
Jean Addington   +79 more
doaj   +2 more sources

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program [PDF]

open access: yesSchizophrenia
Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or ...
Michael P. Harms   +87 more
doaj   +2 more sources

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures [PDF]

open access: yesSchizophrenia
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments.
Daniel H. Mathalon   +107 more
doaj   +2 more sources

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample [PDF]

open access: yesSchizophrenia
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered
Kelly Allott   +97 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy